Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MB | P02144 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5316738 | 0.85 | MEN1 (0.60) | ALDH1A1L3MBTL1HTTSMN1; SMN2MAPT | |
| SCHEMBL11116780 | 0.84 | ALDH1A1 (0.72) | ALDH1A1TP53HIF1AL3MBTL1HTT | |
| SCHEMBL3619479 | 0.82 | ALDH1A1 (0.70) | ALDH1A1TP53HIF1AL3MBTL1HTT | |
| SCHEMBL8238688 | 0.82 | GSK3B (0.59) | ALDH1A1TP53HIF1AGSK3BRAB9A | |
| SCHEMBL4111270 | 0.82 | ALDH1A1 (0.70) | ALDH1A1TP53HIF1AL3MBTL1HTT | |
| SCHEMBL1198090 | 0.81 | GSK3B (0.58) | ALDH1A1TP53HIF1AGSK3BSMN1; SMN2 | |
| SCHEMBL5373557 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TP53HIF1AL3MBTL1HTT | |
| SCHEMBL13198264 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TP53HIF1AL3MBTL1HTT | |
| SCHEMBL10768577 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TP53HIF1AL3MBTL1HTT | |
| SCHEMBL1273600 | 0.81 | ALDH1A1 (1.00) | ALDH1A1TP53HIF1AGSK3BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250276953-A1 | SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-09-04 | — | — | US | disclosed |
| EP-4514768-A2 | SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF | The Regents of the University of Michigan (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20240366590-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| WO-2024005905-A2 | SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| EP-0233051-A2 | Antiarrhythmic Agents | Pfizer Limited (GB) | 1987-08-19 | — | — | EP | disclosed |
| US-4683232-A | N,N-DIMETHYL-P-(2,3-DIHYDRO-2-OXO-6H-1,3,4 OXADIAZIN-2-YLBENZAMIDE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-07-28 | — | — | US | disclosed |
| EP-0189472-A1 | PYRIMIDINONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1986-08-06 | — | — | EP | disclosed |
| EP-0185345-A1 | Imidazo derivatives, their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1986-06-25 | — | — | EP | disclosed |
| US-4587246-A | CARDIOTONIC | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-05-06 | — | — | US | disclosed |
| WO-1986001205-A1 | PYRIMIDINONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1986-02-27 | — | — | WO | disclosed |
| EP-0052442-B1 | HETEROCYCLIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-09-11 | — | — | EP | disclosed |
| US-4503054-A | VASODILATORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-03-05 | — | — | US | disclosed |
| US-4423045-A | CARDIOVASCULAR DISORDERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-12-27 | — | — | US | disclosed |
| EP-0052442-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | ALDH1A1 3985/4885TP53 837/4885HIF1A 4508/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | ALDH1A1 3985/4885TP53 837/4885HIF1A 4508/4885 |
| US-20240366590-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | ALDH1A1 2512/4885TP53 3873/4885HIF1A 2030/4885 |
| US-20250276953-A1 | SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF | SIRT6, SIRT2, SIRT1 | ALDH1A1 2313/4885TP53 123/4885HIF1A 548/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | ALDH1A1 2512/4885TP53 3873/4885HIF1A 2030/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | ALDH1A1 2512/4885TP53 3873/4885HIF1A 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.